SCHEMBL6542371

SCHEMBL6542371

COc1ccc(C=NO)cc1-c1cc2c(cc1C(F)(F)F)C(C)(C)CCC2(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
RARA P10276 1/20 0.36
RARB P10826 1/20 0.36
RARG P13631 1/20 0.36
RAB9A P51151 6/20 0.36
NPC1 O15118 5/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
NFKB1 P19838 3/20 0.36
NFKB2 Q00653 3/20 0.36
RELA Q04206 3/20 0.36
MAPT P10636 6/20 0.36
GAA P10253 2/20 0.36
GFER P55789 1/20 0.35
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.34
PAX8 Q06710 1/20 0.34
KLF5 Q13887 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542368 1.00 ALDH1A1 (0.37) ALDH1A1RARARARBRARGRAB9A
SCHEMBL7054384 0.90 RXRA (0.37) ALDH1A1RAB9ANPC1SMN1; SMN2NFKB1
SCHEMBL7054381 0.90 RXRA (0.37) ALDH1A1RAB9ANPC1SMN1; SMN2NFKB1
SCHEMBL7051783 0.85 RXRA (0.41) ALDH1A1RARARARBRARGRAB9A
SCHEMBL7051785 0.85 RXRA (0.41) ALDH1A1RARARARBRARGRAB9A
SCHEMBL7048842 0.84 RXRA (0.38) ALDH1A1RARARARBRARGRAB9A
SCHEMBL7048839 0.84 RXRA (0.38) ALDH1A1RARARARBRARGRAB9A
SCHEMBL6542648 0.84 NPFFR1 (0.38) RARARARBRARGRAB9ANPC1
SCHEMBL6542643 0.84 NPFFR1 (0.38) RARARARBRARGRAB9ANPC1
SCHEMBL6541656 0.84 RXRA (0.46) ALDH1A1RARARARBRARGRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421061-A4 OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA INCYTE SAN DIEGO INC (US) 2004-12-22 EP disclosed
EP-1421061-A1 OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA Incyte San Diego Incorporated (US) 2004-05-26 EP disclosed
US-20030083357-A1 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia ORTHO MCNEIL PHARMACEUTICAL INC. 2003-05-01 US disclosed
WO-2003016267-A1 OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA INCYTE SAN DIEGO INCORPORATED (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083357-A1 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia OAT, CPT1A, CYP27A1 ALDH1A1 643/4885RARA 1352/4885RARB 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.